NeuroXT develops artificial intelligence software that analyzes brain MRI scans and clinical information to support Alzheimer’s disease assessment and precision treatment research. Its NEXT-Cue product supports cognitive-decline assessment, NEXT-STAGE estimates regional tau burden from MRI for research, and NEXT-SCN studies synaptic integrity and responses to synapse-targeted therapies. The company collaborates with clinical research institutions to validate imaging biomarkers and predict individual treatment responses.
